Ukuqonda ubudlelwano phakathi kwe-MRD kanye ne-CAR T-Cell therapy
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
I-Mesenchymal stem cell therapy ezinkingeni ze-neurological
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
Ukuqokwa kwesidakamizwa sezintandane kunikezwe yi-FDA ku-CART T-Cell Therapy A2B530 yokwelapha umdlavuza we-colorectal.
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
I-Amtagvi ka-Iovance igunyazwe yi-USFDA njengokwelashwa kwe-T-cell yokuqala yesimila esiqinile
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
I-Amivantamab-vmjw igunyazwe yi-USFDA yezinkomba zomdlavuza wamaphaphu we-EGFR exon 20 oguquliwe ongewona omncane weseli
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
I-Osimertinib ene-chemotherapy igunyazwe yi-USFDA ye-EGFR-mutated non-small cell lung cancer.
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
I-Lifileucel igunyazwe yi-USFDA ngemelanoma engasabukeki noma ye-metastatic
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
I-Tepotinib igunyazwe yi-USFDA ngomdlavuza wamaphaphu we-metastatic ongewona omncane
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
I-Irinotecan liposome igunyazwe yi-USFDA yokwelashwa komugqa wokuqala we-metastatic pancreatic adenocarcinoma
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
I-Erdafitinib igunyazwe yi-USFDA nge-carcinoma ye-urothelial ethuthukisiwe endaweni noma ye-metastatic
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..